Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9–26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) v...

Full description

Bibliographic Details
Main Authors: E. D. Moreira, A. R. Giuliano, J. de Hoon, O.-E. Iversen, E. A. Joura, J. Restrepo, P. Van Damme, C. Vandermeulen, M. C. Ellison, A. Krick, C. Shields, B. Heiles, A. Luxembourg
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
9vhpv
cervical canjel code
Online Access:http://dx.doi.org/10.1080/21645515.2017.1403700

Internet

http://dx.doi.org/10.1080/21645515.2017.1403700

Similar Items